drugset / Trial / NCT07843264
PPI Dosing Per CYP2C19 Genotype
RandomizedParallel-groupDouble-blindTreatment
Summary
This study is being done to determine if the dosing of proton pump inhibitor (PPI) medication based on CYP2C19 genotype-derived phenotype leads to improved healing of erosive esophagitis compared to conventional PPI medication dosing.
Timeline
- Start
- 2026-10
- Primary completion
- 2027-12-31
- Completion
- 2028-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pantoprazole | Other / unclassified | 40 mg | — |
| Comparator | Pantoprazole | Other / unclassified | — | — |